Ballenger Trust Selects the Myelin Repair Foundation to Advance Myelin Repair Therapeutic Development for Multiple Sclerosis
Published: Dec 18, 2012
WASHINGTON & SARATOGA, Calif.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF) today announced the support of the Ballenger Trust to accelerate the development of myelin repair therapeutics for multiple sclerosis (MS). The $700,000 gift will provide support for the MRF biomarker project, myelin repair research in human brain tissue and a repurposing opportunity. With the Ballenger Trust’s support, these critical projects will accelerate the Myelin Repair Foundation’s research to develop a myelin repair therapeutic for multiple sclerosis.